Corporate ActionMay 5, 2026, 04:10 PM
OnKure Secures $150M Private Placement; Cash Jumps to $192.1M
AI Summary
OnKure Therapeutics successfully closed a $150.0 million private placement on March 31, 2026, significantly boosting its liquidity. This capital raise increased cash and cash equivalents to $192.1 million and alleviated prior concerns about the company's ability to continue as a going concern for at least the next 12 months. For the first quarter of 2026, the company reported a reduced net loss of $(15.16) million and improved net loss per share of $(1.11), driven by lower operating expenses.
Key Highlights
- Secured $150.0 million in gross proceeds from a 2026 Private Placement on March 31, 2026.
- Cash and cash equivalents increased to $192.1 million as of March 31, 2026, from $59.1 million at December 31, 2025.
- Net loss for Q1 2026 was $(15.16) million, an improvement from $(15.93) million in Q1 2025.
- Basic and diluted net loss per share improved to $(1.11) in Q1 2026 from $(1.19) in Q1 2025.
- Research and development expenses decreased to $11.71 million in Q1 2026 from $13.01 million in Q1 2025.
- Total operating expenses decreased to $15.62 million in Q1 2026 from $17.00 million in Q1 2025.
- Management believes cash and cash equivalents are sufficient to fund operations for at least 12 months, alleviating going concern doubts.